Dinerman Brian F, Skomra Andrew, Dovirak Iryna, Rutkowski John
University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Department of Urology, Buffalo, NY, USA.
University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
Urol Case Rep. 2024 Aug 30;57:102833. doi: 10.1016/j.eucr.2024.102833. eCollection 2024 Nov.
Molecular tumor profiling has become an important diagnostic for prostate cancer, allowing for personalized treatment regimens based on somatic and germline genetic information. We report a 67-year-old patient with metastatic castrate-resistant prostate cancer which was intermittently responsive to androgen-deprivation therapy, docetaxel, abiraterone, radium-223, Sipuleucel-T, and radiotherapy who ultimately demonstrated a remarkable and durable response to pembrolizumab. Our case report underlines the significance of early tumor molecular profiling in aggressive or atypical prostate cancer patients and exhibits the potential for a remarkable clinical response with immunotherapy in candidates with the appropriate tumor profiles.
分子肿瘤分析已成为前列腺癌的一项重要诊断方法，可根据体细胞和种系遗传信息制定个性化治疗方案。我们报告了一名67岁的转移性去势抵抗性前列腺癌患者，该患者对雄激素剥夺疗法、多西他赛、阿比特龙、镭-223、西妥昔单抗和放疗呈间歇性反应，最终对派姆单抗表现出显著且持久的反应。我们的病例报告强调了早期肿瘤分子分析在侵袭性或非典型前列腺癌患者中的重要性，并展示了免疫疗法在具有合适肿瘤特征的患者中产生显著临床反应的潜力。
